ABCM
NASDAQAbcam plc
Abcam plc (ABCM) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for ABCM in the last 30 days. The most recent was published Feb 12, 2024.
Latest news
25 items- 13D/GSEC Form SC 13G/A filed by Abcam plc (Amendment)SC 13G/A - Abcam plc (0001492074) (Subject)
- 13D/GSEC Form SC 13G/A filed by Abcam plc (Amendment)SC 13G/A - Abcam plc (0001492074) (Subject)
- SECSEC Form 15-12G filed by Abcam plc15-12G - Abcam plc (0001492074) (Filer)
- SECSEC Form S-8 POS filed by Abcam plcS-8 POS - Abcam plc (0001492074) (Filer)
- SECSEC Form S-8 POS filed by Abcam plcS-8 POS - Abcam plc (0001492074) (Filer)
- SECSEC Form S-8 POS filed by Abcam plcS-8 POS - Abcam plc (0001492074) (Filer)
- SECSEC Form POSASR filed by Abcam plcPOSASR - Abcam plc (0001492074) (Filer)
- 13D/GSEC Form SC 13D/A filed by Abcam plc (Amendment)SC 13D/A - Abcam plc (0001492074) (Subject)
- SECSEC Form 25-NSE filed by Abcam plc25-NSE - Abcam plc (0001492074) (Subject)
- PRDanaher Completes Acquisition of AbcamWASHINGTON, Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023. As a result, Abcam has become an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended. The consideration due to former Abcam shareholders will be settled pursuant to the terms of the Scheme and the consideration due to former Abcam ADS
- SECSEC Form 6-K filed by Abcam plc6-K - Abcam plc (0001492074) (Filer)
- NEWSAcquisition Of Abcam By Danaher For $24.00 Per Share In Cash Approved By The High Court Of Justice Of England And WalesAbcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme.Closing of the Transact
- SECSEC Form 6-K filed by Abcam plc6-K - Abcam plc (0001492074) (Filer)
- PRAcquisition of Abcam by Danaher Approved by the High Court of Justice of England and WalesAbcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘). Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme. Closing of the T
- 13D/GSEC Form SC 13D/A filed by Abcam plc (Amendment)SC 13D/A - Abcam plc (0001492074) (Subject)
- 13D/GSEC Form SC 13D/A filed by Abcam plc (Amendment)SC 13D/A - Abcam plc (0001492074) (Subject)
- SECSEC Form 6-K filed by Abcam plc6-K - Abcam plc (0001492074) (Filer)
- NEWSAbcam Has Obtained All Clearances Required In Connection With Proposed Acquisition By Danaher For $24.00 Per Share In Cash
- PRAbcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), today announced that all Identified Clearances required in connection with the Transaction have been obtained from the relevant Governmental Authorities. The Transaction remains subject to the sanction of the Scheme by the High Court of Justice of England and Wales and the satisfaction or waiver (if applicable) of certain other customary closing conditions as set out in Par
- SECSEC Form 6-K filed by Abcam plc6-K - Abcam plc (0001492074) (Filer)
- NEWSAbcam Shareholders Approve Proposed Acquisition By Danaher
- PRShareholders of Abcam Approve Proposed Acquisition by DanaherAbcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher'), today announced that its shareholders have approved the proposal for Danaher to acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction'). "On behalf of Abcam's Board of Directors, I would like to thank all our shareholders for their support for the Transaction," said Peter Allen, Chairman of the Board. "With this approval, we are focused on moving swiftly toward transaction close and
- 13D/GSEC Form SC 13D/A filed by Abcam plc (Amendment)SC 13D/A - Abcam plc (0001492074) (Subject)
- PRStatement from Dr. Jonathan Milner on the suspension of the "Vote AGAINST" campaignStatement from Dr. Jonathan Milner on the suspension of the "Vote AGAINST" campaign CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.16% of the Company, today issued the following statement in relation to the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher"). "After extensive feedback from the majority of Abcam's shareholders, I have today decided to suspend my "Vote AGAINST" campaign. It has become clear that a significant majority intend to support Danaher's acquisition of Abcam and I respect this decision and will not stan
- NEWSRBC Capital Maintains Sector Perform on Abcam, Lowers Price Target to $24RBC Capital analyst Alistair Campbell maintains Abcam (NASDAQ:ABCM) with a Sector Perform and lowers the price target from $25 to $24.
ABCM FAQ
8 questionsWhat does Abcam plc do?
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas...What is the latest news on ABCM?
Quantisnow has not tracked any new filings, ratings or press releases for ABCM in the last 30 days. The most recent wire item was published on February 12, 2024.Where does ABCM stock trade?
Abcam plc (ABCM) is listed on NASDAQ.What sector and industry is ABCM in?
Abcam plc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Abcam plc go public?
Abcam plc (ABCM) completed its IPO in 2020.What are analysts saying about ABCM?
Across the last 3 analyst actions on Abcam plc, there were 1 upgrade and 1 downgrade. The most recent action was from RBC Capital Mkts: Sector Perform with a $22.00 price target on 2023-06-20. Recent price targets range from $15.00 to $25.00.What companies are similar to ABCM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ABCM side-by-side with any of them on Quantisnow.How can I track ABCM on Quantisnow?
Quantisnow aggregates Abcam plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABCM to receive live email and push alerts on every new disclosure.